Recognizing PML Symptoms in Tysabri Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Occupational Risk Awareness

If you or a loved one is taking Tysabri and experiencing new neurological symptoms, understanding the signs of progressive multifocal leukoencephalopathy (PML) is critical. The medical community has long recognized that early detection of PML can improve outcomes, and this page outlines the key symptoms to watch for and what steps to take next.

Tysabri and the Risk of Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn disease. Its prescribing information carries a boxed warning stating that the drug increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, but Tysabri-treated patients have developed the disease even in the absence of other immunosuppressive conditions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Monitoring of PML

The clinical presentation of PML can be subtle and variable. A large retrospective cohort study of 456 Italian PML patients observed between 1987 and 2024 described the demographic, clinical, radiological, and laboratory characteristics of the disease (https://pubmed.ncbi.nlm.nih.gov/40922664/). PML is a severe demyelinating disease, and its symptoms often include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. In Tysabri-treated patients, healthcare professionals are instructed to monitor for any new sign or symptom that may be suggestive of PML and to withhold Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves the drug's action on the immune system. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of lymphocytes into the brain. This reduces inflammation in multiple sclerosis but also impairs immune surveillance against JCV, allowing the virus to reactivate and cause PML. The risk increases with longer exposure because the duration of immune suppression accumulates over time. FDA adverse-event reports (FAERS) provide additional context on the range of adverse effects associated with Tysabri. The most frequently reported events include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), and memory impairment (7,895 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly quantify PML incidence, they underscore the importance of monitoring for neurological symptoms that could overlap with PML presentation.

Legal Considerations for Tysabri-Related PML

For patients who develop PML after Tysabri exposure, the timeline between drug initiation and harm can vary. The known risk factors include treatment duration beyond two years, but PML has been reported earlier in patients with additional risk factors such as prior immunosuppressant use or positive anti-JCV antibody status (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that these factors should be considered when initiating and continuing therapy. From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a central concern. The prescribing information includes a boxed warning, which is the strongest safety communication required by the FDA. However, patients and healthcare providers must understand that PML can occur even when risk factors are managed. The TOUCH program is designed to ensure that patients are informed of the risks and that monitoring occurs, but it does not eliminate the possibility of PML. Attorney-related considerations for affected patients include the need to document the timeline of Tysabri exposure, the presence of any known risk factors, and the clinical course of PML. Patients who develop PML may face severe disability or death, and legal action may be pursued if there is evidence that warnings were inadequate or that the drug was prescribed without proper consideration of risk factors. The boxed warning explicitly states that PML usually leads to death or severe disability, which underscores the gravity of the harm (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and why is it associated with PML?

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The drug works by blocking immune cells from entering the brain, which can allow the virus to reactivate. The prescribing information includes a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three main risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be considered when deciding to start or continue Tysabri therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal options are available for patients who developed PML after Tysabri use?

Patients who develop PML may have legal recourse if they believe the risks were not adequately communicated or managed. Legal action may involve documenting the timeline of Tysabri exposure, risk factors, and the clinical course of PML. An attorney can help evaluate whether warnings were sufficient and whether the drug was prescribed appropriately.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.